The stock price of Oragenics Inc (AMEX: OGEN) has dropped by -8.29 compared to previous close of 0.39. Despite this, the company has seen a fall of -15.50% in its stock price over the last five trading days. globenewswire.com reported 2024-10-09 that SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company’s progress throughout 2024, including key milestones in the development of ONP-002, its lead candidate for the treatment of concussions.
Is It Worth Investing in Oragenics Inc (AMEX: OGEN) Right Now?
The stock has a 36-month beta value of 0.46. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OGEN is 7.66M, and at present, short sellers hold a 1.54% of that float. On October 14, 2024, the average trading volume of OGEN was 732.98K shares.
OGEN’s Market Performance
OGEN’s stock has seen a -15.50% decrease for the week, with a -29.02% drop in the past month and a -69.92% fall in the past quarter. The volatility ratio for the week is 12.51%, and the volatility levels for the past 30 days are at 9.62% for Oragenics Inc The simple moving average for the past 20 days is -16.13% for OGEN’s stock, with a -81.11% simple moving average for the past 200 days.
OGEN Trading at -54.73% from the 50-Day Moving Average
After a stumble in the market that brought OGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.41% of loss for the given period.
Volatility was left at 9.62%, however, over the last 30 days, the volatility rate increased by 12.51%, as shares sank -32.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -64.86% lower at present.
During the last 5 trading sessions, OGEN fell by -15.50%, which changed the moving average for the period of 200-days by -93.40% in comparison to the 20-day moving average, which settled at $0.4232. In addition, Oragenics Inc saw -93.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OGEN starting from Telling Fred, who sale 3,500 shares at the price of $3.57 back on Nov 30 ’23. After this action, Telling Fred now owns 38,345 shares of Oragenics Inc, valued at $12,488 using the latest closing price.
Stock Fundamentals for OGEN
Current profitability levels for the company are sitting at:
- 310.84 for the present operating margin
- 418.96 for the gross margin
The net margin for Oragenics Inc stands at 646.51. The total capital return value is set at -7.07. Equity return is now at value -454.72, with -349.31 for asset returns.
Currently, EBITDA for the company is -20.88 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of -57.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
To sum up, Oragenics Inc (OGEN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
